{"id":"choriogonadotropin-alfa","rwe":[{"pmid":"41473569","year":"2025","title":"Optimal timing for triggering oocyte maturation during in vitro fertilization cycles varies between gonadotropin-releasing hormone agonist and human chorionic gonadotropin use.","finding":"","journal":"F&S reports","studyType":"Clinical Study"},{"pmid":"41426754","year":"2025","title":"IgA Vasculitis With Nephritis Following Controlled Ovarian Stimulation and Oocyte Donation.","finding":"","journal":"Cureus","studyType":"Clinical Study"},{"pmid":"40142278","year":"2025","title":"Comparison of Effects of Chorionic Gonadotropin Alfa and Anastrozole on Sperm Retrieval Rate in Patients with Non-Mosaic Klinefelter Syndrome Following Microdissection Testicular Sperm Extraction.","finding":"","journal":"Medicina (Kaunas, Lithuania)","studyType":"Clinical Study"},{"pmid":"38775072","year":"2024","title":"Circadian serum progesterone variations on the day of frozen embryo transfer in a modified natural cycle protocol.","finding":"","journal":"Human reproduction (Oxford, England)","studyType":"Clinical Study"},{"pmid":"38299472","year":"2024","title":"Dose accuracy of the follitropin alfa pen injector 2.0, the follitropin alfa:lutropin alfa 2:1 combination pen injector 2.0 and the choriogonadotropin alfa pen injector 1.0 used for fertility treatment.","finding":"","journal":"Expert opinion on drug delivery","studyType":"Clinical Study"}],"_fda":{"id":"11f90621-6a2d-4c75-9f32-3e6180df7618","set_id":"1e94155f-19be-4944-b197-be4edbb4faf9","openfda":{"rxcui":["896854","896856"],"spl_id":["11f90621-6a2d-4c75-9f32-3e6180df7618"],"brand_name":["Pregnyl"],"spl_set_id":["1e94155f-19be-4944-b197-be4edbb4faf9"],"package_ndc":["78206-150-01","78206-150-99","78206-151-89"],"product_ndc":["78206-150"],"generic_name":["CHORIOGONADOTROPIN ALFA"],"product_type":["HUMAN PRESCRIPTION DRUG"],"manufacturer_name":["Organon LLC"],"application_number":["BLA017692"],"is_original_packager":[true]},"version":"11","warnings":["WARNINGS Use hCG in conjunction with gonadotropin therapy only if the physician is experienced with infertility problems and is familiar with the criteria for patient selection, contraindications, warnings, precautions, and adverse reactions described in the package insert for gonadotropins. Gonadotropin therapy, including hCG, requires a certain time commitment by physicians and supportive health professionals, and requires the availability of appropriate monitoring facilities (see PRECAUTIONS/Laboratory Tests ). Safe and effective induction of ovulation with use of PREGNYL requires monitoring of ovarian response with serum estradiol and transvaginal ultrasound on a regular basis. Anaphylaxis Anaphylaxis has been reported with urinary-derived hCG products. Ovarian Hyperstimulation Syndrome (OHSS) Ovarian Hyperstimulation Syndrome (OHSS) is a medical event distinct from uncomplicated ovarian enlargement and may progress rapidly to become a serious medical event. OHSS is characterized by a dramatic increase in vascular permeability, which can result in a rapid accumulation of fluid in the peritoneal cavity, thorax, and potentially, the pericardium. The early warning signs of the development of OHSS are severe pelvic pain, nausea, vomiting, and weight gain. Abdominal pain, abdominal distension, gastrointestinal symptoms including nausea, vomiting and diarrhea, severe ovarian enlargement, weight gain, dyspnea, and oliguria have been reported with OHSS. Clinical evaluation may reveal hypovolemia, hemoconcentration, electrolyte imbalances, ascites, hemoperitoneum, pleural effusions, hydrothorax, acute pulmonary distress, and thromboembolic reactions. Transient liver function test abnormalities suggestive of hepatic dysfunction with or without morphologic changes on liver biopsy, have been reported in association with OHSS. OHSS occurs after gonadotropin treatment has been discontinued and it can develop rapidly, reaching its maximum about seven to ten days following treatment. Usually, OHSS resolves spontaneously with the onset of menses. If there is evidence that OHSS may be developing prior to hCG administration, withhold hCG. Cases of OHSS are more common, more severe, and more protracted if pregnancy occurs; therefore, assess women for the development of OHSS for at least two weeks after hCG administration. Severe OHSS may be life-threatening. Monitor women undergoing ovarian stimulation for early signs and symptoms of OHSS. Women with known risk factors for a high ovarian response may be especially prone to the development of OHSS during or following treatment with PREGNYL. Adherence to the recommended PREGNYL dose and treatment regimen and careful monitoring of ovarian response is important to reduce the risk of OHSS. If serious OHSS occurs, stop gonadotropins, including hCG, and consider whether the woman should be hospitalized. Treatment is primarily symptomatic and overall consists of bed rest, fluid and electrolyte management, and analgesics (if needed). Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. Initiate early consultation with a physician experienced in the management of OHSS and fluid and electrolyte imbalances. Pulmonary and Vascular Complications Serious pulmonary conditions (e.g., atelectasis, acute respiratory distress syndrome) have been reported in women treated with gonadotropins. In addition, thromboembolic reactions both in association with, and separate from OHSS have been reported following gonadotropin therapy. Intravascular thrombosis, which may originate in venous or arterial vessels, can result in reduced blood flow to vital organs or the extremities. Women with generally recognized risk factors for thrombosis, such as a personal or family history, severe obesity, or thrombophilia, may have an increased risk of venous or arterial thromboembolic events, during or following treatment with gonadotropins. Sequelae of such reactions have included venous thrombophlebitis, pulmonary embolism, pulmonary infarction, cerebral vascular occlusion (stroke), and arterial occlusion resulting in loss of limb and rarely in myocardial infarction. In rare cases, pulmonary complications and/or thromboembolic reactions have resulted in death. In women with recognized risk factors, the benefits of ovulation induction, in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) treatment need to be weighed against the risks. Pregnancy itself also carries an increased risk of thrombosis. Ovarian Torsion Ovarian torsion has been reported after treatment with gonadotropins, including PREGNYL. Ovarian torsion may be related to other conditions, such as OHSS, pregnancy, previous abdominal surgery, past history of ovarian torsion, and previous or current ovarian cysts. Damage to the ovary due to reduced blood supply can be limited by early diagnosis and immediate detorsion. Multi-Fetal Gestation and Birth Multi-fetal gestation and births have been reported with all gonadotropin therapy including hCG. Advise women of the potential risk of multiple births before starting treatment with gonadotropins including PREGNYL. Congenital Malformations The incidence of congenital malformations after ART may be slightly higher than after spontaneous conceptions. This slightly higher incidence is thought to be related to differences in parental characteristics (e.g., maternal age, sperm characteristics) and to the higher incidence of multiple gestations after ART. There are no indications that the use of gonadotropins during ART is associated with an increased risk of congenital malformations. Ectopic Pregnancy Infertile women undergoing Assisted Reproductive Technologies (ART) have an increased incidence of ectopic pregnancy. Early ultrasound confirmation that a pregnancy is intrauterine is therefore important. Spontaneous Abortion The risk of spontaneous abortion (miscarriage) is increased with gonadotropin products. However, causality has not been established. The increased risk may be a factor of the underlying infertility. Ovarian Neoplasms There have been infrequent reports of ovarian neoplasms, both benign and malignant, in women who have undergone multiple drug therapy for ovarian stimulation; however, a causal relationship has not been established."],"pregnancy":["Pregnancy PREGNYL is not indicated in pregnancy. PREGNYL may be used for luteal phase support, but is discontinued upon confirmation of pregnancy. There are no data on the use of hCG in pregnancy. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively."],"description":["DESCRIPTION Chorionic gonadotropin, a gonadotropin, is a polypeptide hormone produced by the human placenta and obtained from the urine of pregnant persons. Chorionic gonadotropin is a purified preparation composed of an alpha and a beta subunit. The alpha subunit is essentially identical to the alpha subunits of the human pituitary gonadotropins, luteinizing hormone (LH) and follicle-stimulating hormone (FSH), as well as to the alpha subunit of human thyroid-stimulating hormone (TSH). The beta subunits of these hormones differ in amino acid sequence. PREGNYL ® (chorionic gonadotropin) for injection is a sterile, dried powder for intramuscular injection after reconstitution. Each multiple-dose vial is only for use in one patient and contains 10,000 USP units of chorionic gonadotropin with dibasic sodium phosphate (4.4 mg) and monobasic sodium phosphate (5 mg). If required, pH is adjusted with sodium hydroxide and/or phosphoric acid. Each package also contains a 10-mL vial of solvent containing: water for injection with 0.56% sodium chloride and 0.9% BENZYL ALCOHOL (preservative), WHICH IS NOT FOR USE IN NEWBORNS. If required, pH is adjusted with sodium hydroxide and/or hydrochloric acid."],"precautions":["PRECAUTIONS General Induction of androgen secretion by hCG may cause fluid retention. Use hCG with caution in patients with cardiac or renal disease, hypertension, epilepsy, migraine, or asthma. Careful attention should be given to the diagnosis of infertility in candidates for hCG therapy (see INDICATIONS AND USAGE ). Evaluate patients for uncontrolled non-gonadal endocrinopathies (e.g., thyroid, adrenal or pituitary disorders) and provide the appropriate specific treatment. Information for Patients Prior to therapy with hCG, patients should be informed of the duration of treatment and monitoring of their condition that will be required. The risks of Ovarian Hyperstimulation Syndrome and multiple births in women (see WARNINGS ) and other possible adverse reactions (see ADVERSE REACTIONS ) should also be discussed. Laboratory Tests In most instances, treatment of women with FSH results only in follicular recruitment and development. In the absence of an endogenous LH surge, hCG is given when monitoring of the patient indicates that sufficient follicular development has occurred. This may be estimated by pelvic ultrasound alone or in combination with measurement of serum estradiol levels. The combination of both pelvic ultrasound and serum estradiol measurement are useful for monitoring the development of follicles, for timing of the ovulatory trigger, as well as for detecting ovarian enlargement and minimizing the risk of the Ovarian Hyperstimulation Syndrome and multiple gestation. Confirm the number of growing follicles using ultrasonography because serum estrogens do not give an indication of the size or number of follicles. Human chorionic gonadotropins can crossreact in the radioimmunoassay of gonadotropins, especially luteinizing hormone. Each individual laboratory should establish the degree of crossreactivity with their gonadotropin assay. Make the laboratory aware that the patient is on hCG, if gonadotropin levels are requested. The clinical confirmation of ovulation, with the exception of pregnancy, is obtained by direct and indirect indices of progesterone production as well as sonographic evidence of ovulation. The indices most generally used are as follows: A rise in basal body temperature Increase in serum progesterone and Menstruation following a shift in basal body temperature Urinary or serum luteinizing hormone (LH) rise When used in conjunction with the indices of progesterone production, sonographic visualization of the ovaries will assist in determining if ovulation has occurred. Sonographic evidence of ovulation may include the following: Fluid in the cul-de-sac Collapsed follicle Features consistent with corpus luteum formation (e.g., ovarian stigmata, secretory endometrium) Accurate interpretation of the indices of ovulation requires a physician who is experienced in the interpretation of these tests. Sonographic evaluation of the early pregnancy is also important to rule out ectopic pregnancy. Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term studies in animals have not been performed to evaluate the carcinogenic or mutagenic potential of chorionic gonadotropin. Pregnancy PREGNYL is not indicated in pregnancy. PREGNYL may be used for luteal phase support, but is discontinued upon confirmation of pregnancy. There are no data on the use of hCG in pregnancy. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Pediatric Use Induction of androgen secretion by hCG may induce precocious puberty in pediatric patients treated for cryptorchidism. Discontinue therapy if signs of precocious puberty occur. Lactation It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised if hCG is administered to a nursing woman. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for PREGNYL and any potential adverse effects on the breastfed child from PREGNYL or from the underlying maternal condition. Geriatric Use Clinical studies of PREGNYL (chorionic gonadotropin) for injection did not include subjects aged 65 and over."],"how_supplied":["HOW SUPPLIED Two-vial package containing: One 10 mL multiple-dose vial for administration by one patient, containing lyophilized powder of 10,000 USP units of chorionic gonadotropin per vial, NDC 78206-150-01. One 10 mL multiple-dose vial of solvent containing: water for injection with sodium chloride 0.56% and benzyl alcohol (preservative) 0.9%, NDC 78206-151-89. Storage: Store unopened vial at controlled room temperature 15°C to 25°C (59°F to 77°F). If reconstituted solution in vial is not used immediately, then store refrigerated [2°C to 8°C (36°F to 46°F)] until use and discard after 60 days. Do not shake. Do not freeze."],"geriatric_use":["Geriatric Use Clinical studies of PREGNYL (chorionic gonadotropin) for injection did not include subjects aged 65 and over."],"pediatric_use":["Pediatric Use Induction of androgen secretion by hCG may induce precocious puberty in pediatric patients treated for cryptorchidism. Discontinue therapy if signs of precocious puberty occur."],"effective_time":"20251202","adverse_reactions":["ADVERSE REACTIONS For males and females: Immune system disorders Hypersensitivity reactions, both localized and systemic in nature, including anaphylaxis have been reported. In rare cases, generalized rash or fever may occur (see CONTRAINDICATIONS and WARNINGS ). If a hypersensitivity reaction is suspected, discontinue PREGNYL and assess for other potential causes for the event. Psychiatric disorders Irritability Restlessness Depression Nervous system disorders Headache General disorders and administration site conditions PREGNYL may cause reactions at the site of injection, such as bruising, pain, redness, swelling and itching. Occasionally, allergic reactions have been reported, mostly manifesting as pain and/or rash at the injection site (see CONTRAINDICATIONS and WARNINGS ). Edema Fatigue In the female: Vascular disorders In rare instances, thromboembolism has been associated with FSH/hCG therapy, usually associated with severe OHSS (see WARNINGS ). Respiratory, thoracic and mediastinal disorders Hydrothorax, as a complication of severe OHSS (see WARNINGS ). Gastrointestinal disorders Abdominal pain and gastrointestinal symptoms such as nausea and diarrhea, related to mild OHSS. Ascites, as a complication of severe OHSS (see WARNINGS ). Reproductive system and breast disorders Unwanted ovarian hyperstimulation, mild or severe Ovarian Hyperstimulation Syndrome (see WARNINGS ). Mild to moderate enlargement of ovaries and ovarian cysts related to mild OHSS. Large ovarian cysts (prone to rupture), usually associated with severe OHSS (see WARNINGS ). Painful breasts Investigations Weight gain as a characteristic of severe OHSS (see WARNINGS ). In the male: Metabolism and nutrition disorders Water and sodium retention is occasionally seen after administration of high dosages; this is regarded as a result of excessive androgen production. Reproductive system and breast disorders HCG treatment may sporadically cause gynecomastia. Precocious puberty"],"contraindications":["CONTRAINDICATIONS Prior hypersensitivity reactions to human gonadotropins, including hCG, or any of the excipients (see ADVERSE REACTIONS ). High serum FSH, indicating primary gonadal failure in women. Presence of uncontrolled non-gonadal endocrinopathies (e.g., thyroid, adrenal, or pituitary disorders). Tumors of the hypothalamus or pituitary gland and ovary, breast, or uterus in females and breast or prostate in males. Malformations of the reproductive organs incompatible with pregnancy. Fibroid tumors of the uterus incompatible with pregnancy. Abnormal vaginal bleeding of undetermined origin."],"storage_and_handling":["Storage: Store unopened vial at controlled room temperature 15°C to 25°C (59°F to 77°F). If reconstituted solution in vial is not used immediately, then store refrigerated [2°C to 8°C (36°F to 46°F)] until use and discard after 60 days. Do not shake. Do not freeze."],"clinical_pharmacology":["CLINICAL PHARMACOLOGY The action of human chorionic gonadotropin (hCG) is virtually identical to that of pituitary LH, although hCG appears to have a small degree of FSH activity as well. It stimulates production of gonadal steroid hormones by stimulating the interstitial cells (Leydig cells) of the testis to produce androgens and the corpus luteum of the ovary to produce progesterone. Androgen stimulation in the male leads to the development of secondary sex characteristics and may stimulate testicular descent when no anatomical impediment to descent is present. This descent is usually reversible when hCG is discontinued. During the normal menstrual cycle, LH participates with FSH in the development and maturation of the normal ovarian follicle, and the mid-cycle LH surge triggers ovulation. hCG can substitute for LH in this function. During a normal pregnancy, hCG secreted by the placenta maintains the corpus luteum after LH secretion decreases, supporting continued secretion of estrogen and progesterone and preventing menstruation. HCG HAS NO KNOWN EFFECT ON FAT MOBILIZATION, APPETITE OR SENSE OF HUNGER, OR BODY FAT DISTRIBUTION."],"indications_and_usage":["INDICATIONS AND USAGE HCG HAS NOT BEEN DEMONSTRATED TO BE EFFECTIVE ADJUNCTIVE THERAPY IN THE TREATMENT OF OBESITY. THERE IS NO SUBSTANTIAL EVIDENCE THAT IT INCREASES WEIGHT LOSS BEYOND THAT RESULTING FROM CALORIC RESTRICTION, THAT IT CAUSES A MORE ATTRACTIVE OR “NORMAL” DISTRIBUTION OF FAT, OR THAT IT DECREASES THE HUNGER AND DISCOMFORT ASSOCIATED WITH CALORIE-RESTRICTED DIETS. Prepubertal cryptorchidism not due to anatomical obstruction. In general, hCG is thought to induce testicular descent in situations when descent would have occurred at puberty. hCG thus may help predict whether or not orchiopexy will be needed in the future. Although, in some cases, descent following hCG administration is permanent, in most cases, the response is temporary. Therapy is usually instituted in children between the ages of 4 and 9. Selected cases of hypogonadotropic hypogonadism (hypogonadism secondary to a pituitary deficiency) in males. Induction of ovulation and pregnancy in the anovulatory, infertile woman in whom the cause of anovulation is secondary and not due to primary ovarian failure, and who has been appropriately treated with human gonadotropins."],"spl_unclassified_section":["PREGNYL manufactured by: Organon USA LLC, a subsidiary of ORGANON & Co., Jersey City, NJ 07302, USA U.S. License No. 2331 PREGNYL Solvent manufactured by: Simtra US LLC Bloomington, IN 47403, USA For patent information: www.organon.com/our-solutions/patent/ © 2025 Organon group of companies. All rights reserved. Revised: 03/2025 uspi-og8829-pwi-2503r002 Rx only"],"dosage_and_administration":["DOSAGE AND ADMINISTRATION For intramuscular use only. Each multiple-dose vial is to be used for one patient. The dosage regimen employed in any particular case will depend upon the indication for the use, the age and weight of the patient, and the physician’s preference. The following regimens have been advocated by various authorities: Prepubertal cryptorchidism not due to anatomical obstruction. Generally, institute therapy in children between the ages of 4 and 9. 4000 USP units 3 times weekly for 3 weeks. 5000 USP units every second day for 4 injections. 15 injections for 500 to 1000 USP units over a period of 6 weeks. 500 USP units 3 times weekly for 4 to 6 weeks. If this course of treatment is not successful, another series is begun 1 month later, giving 1000 USP units per injection. Selected cases of hypogonadotropic hypogonadism in males. 500 to 1000 USP units 3 times a week for 3 weeks, followed by the same dose twice a week for 3 weeks. 4000 USP units 3 times weekly for 6 to 9 months, following which the dosage may be reduced to 2000 USP units 3 times weekly for an additional 3 months. Induction of ovulation and pregnancy in the anovulatory, infertile woman in whom the cause of anovulation is secondary and not due to primary ovarian failure and who has been appropriately treated with gonadotropins. (See also prescribing information for gonadotropins for dosage and administration for that drug product .) 5000 to 10,000 USP units 1 day following the last dose of gonadotropins. (A dosage of 10,000 USP units is recommended in the labeling for gonadotropins.) Directions for Reconstitution Withdraw sterile air from vial with lyophilized powder and inject into vial with solvent. Remove 1 to 10 mL of solvent and add to vial with lyophilized powder; agitate gently until powder is completely dissolved in solution. Do not shake. PREGNYL is a white, dry powder / cake. The solvent is a clear and colorless aqueous solution. Visually inspect parenteral drug products for particulate matter and discoloration prior to administration, whenever solution and container permit. If there is a discoloration or particulates, do not use. IMPORTANT: IF NEEDED, THE RECONSTITUTED SOLUTION IS STABLE FOR 60 DAYS WHEN REFRIGERATED. DO NOT FREEZE. USE THE RECONSTITUTED SOLUTION WITHIN 60 DAYS OF RECONSTITUTION. IF THE RECONSTITUTED SOLUTION IS NO LONGER NEEDED, DISCARD UNUSED PORTION."],"spl_product_data_elements":["Pregnyl CHORIOGONADOTROPIN ALFA Pregnyl CHORIOGONADOTROPIN ALFA CHORIOGONADOTROPIN ALFA CHORIOGONADOTROPIN ALFA SODIUM PHOSPHATE, MONOBASIC, UNSPECIFIED FORM SODIUM PHOSPHATE, DIBASIC, UNSPECIFIED FORM SODIUM HYDROXIDE PHOSPHORIC ACID Pregnyl solvent WATER, SODIUM CHLORIDE and BENZYL ALCOHOL WATER SODIUM CHLORIDE BENZYL ALCOHOL"],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL - Kit Carton NDC 78206-150-01 Chorionic Gonadotropin Pregnyl ® for Injection 10,000 USP units/vial For Intramuscular Injection Only Contents: One multiple-dose vial containing chorionic gonadotropin One multiple-dose vial of solvent Dispense with Full Prescribing Information Rx only PRINCIPAL DISPLAY PANEL - Kit Carton"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term studies in animals have not been performed to evaluate the carcinogenic or mutagenic potential of chorionic gonadotropin."]},"tags":[{"label":"Gonadotropin","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Lutropin-choriogonadotropic hormone receptor","category":"target"},{"label":"LHCGR","category":"gene"},{"label":"G03GA08","category":"atc"},{"label":"Subcutaneous","category":"route"},{"label":"Injection","category":"form"},{"label":"Active","category":"status"},{"label":"Ulcerative colitis","category":"indication"},{"label":"Emd Serono","category":"company"},{"label":"Approved 2000s","category":"decade"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"OVARIAN HYPERSTIMULATION SYNDROME","source":"FDA FAERS","actionTaken":"590 reports"},{"date":"","signal":"NO ADVERSE EVENT","source":"FDA FAERS","actionTaken":"208 reports"},{"date":"","signal":"PRODUCT DOSE OMISSION ISSUE","source":"FDA FAERS","actionTaken":"108 reports"},{"date":"","signal":"ABDOMINAL DISTENSION","source":"FDA FAERS","actionTaken":"95 reports"},{"date":"","signal":"ASCITES","source":"FDA FAERS","actionTaken":"85 reports"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"85 reports"},{"date":"","signal":"INAPPROPRIATE SCHEDULE OF DRUG ADMINISTRATION","source":"FDA FAERS","actionTaken":"83 reports"},{"date":"","signal":"PRODUCT PACKAGING QUANTITY ISSUE","source":"FDA FAERS","actionTaken":"83 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"82 reports"},{"date":"","signal":"ABDOMINAL PAIN","source":"FDA FAERS","actionTaken":"80 reports"}],"commonSideEffects":[{"effect":"At Least One Adverse Event","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Application Site Disorders","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Injection Site Pain","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Gastro-Intestinal System Disorders","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Abdominal Pain","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Nausea","drugRate":"","severity":"mild","_validated":false,"_confidence":0.3},{"effect":"Vomiting","drugRate":"","severity":"mild","_validated":false,"_confidence":0.3},{"effect":"Secondary Terms (Post-Operative Pain)","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Injection Site Bruising","drugRate":"","severity":"mild","_validated":false,"_confidence":0.3},{"effect":"Injection site inflammation","drugRate":"","severity":"mild","_validated":false,"_confidence":0.3},{"effect":"Injection site reaction","drugRate":"","severity":"mild","_validated":false,"_confidence":0.3},{"effect":"Reproductive Disorders, Female","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Ovarian cyst","drugRate":"","severity":"mild","_validated":false,"_confidence":0.3},{"effect":"Ovarian hyperstimulation","drugRate":"","severity":"mild","_validated":false,"_confidence":0.3},{"effect":"Spontaneous Abortion","drugRate":"reported","severity":"unknown"},{"effect":"Ectopic Pregnancy","drugRate":"reported","severity":"unknown"},{"effect":"Premature Labor","drugRate":"reported","severity":"unknown"},{"effect":"Postpartum Fever","drugRate":"reported","severity":"unknown"},{"effect":"Congenital Abnormalities","drugRate":"reported","severity":"unknown"},{"effect":"Pulmonary and vascular complications","drugRate":"reported","severity":"unknown"},{"effect":"Adnexal torsion","drugRate":"reported","severity":"unknown"},{"effect":"Mild to moderate ovarian enlargement","drugRate":"reported","severity":"unknown"},{"effect":"Hemoperitoneum","drugRate":"reported","severity":"unknown"},{"effect":"Allergic reactions","drugRate":"reported","severity":"unknown"},{"effect":"Thromboembolic events","drugRate":"reported","severity":"unknown"}],"specialPopulations":{"Pregnancy":"Intrauterine death and impaired parturition were observed in pregnant rats given dose of urinary-hCG (500 IU) equivalent to three times the maximum human dose of 10,000 USP, based on body surface area.","Geriatric use":"Safety and effectiveness in geriatric patients has not been established.","Paediatric use":"Safety and effectiveness in pediatric patients has not been established."}},"trials":[],"aliases":[],"company":"Merck KGaA","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=CHORIOGONADOTROPIN ALFA","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:22:21.637224+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:22:28.007289+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T00:22:20.272959+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CHORIOGONADOTROPIN ALFA","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:22:28.820219+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:22:18.595293+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T00:22:30.593364+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Luteinizing hormone/Choriogonadotropin receptor agonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:22:29.678111+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201464/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:22:29.536830+00:00"},"safety.commonSideEffects":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"ADVERSE REACTIONS For males and females: Immune system disorders Hypersensitivity reactions, both localized and systemic in nature, including anaphylaxis have been reported. In rare cases, generalized rash or fever may occur (see CONTRAINDICATIONS and WARNINGS ). If a hypersensitivity reaction is suspected, discontinue PREGNYL and assess for other potential causes for the event. Psychiatric disorders Irritability Restlessness Depression Nervous system disorders Headache General disorders and adm","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:22:34.086061+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"BLA017692","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:22:18.595345+00:00"}},"allNames":"ovidrel","offLabel":[],"synonyms":["choriogonadotropin alfa","ovidrel","ovitrelle"],"timeline":[{"date":"2000-09-20","type":"positive","source":"DrugCentral","milestone":"FDA approval (Emd Serono)"}],"approvals":[{"date":"2000-09-20","orphan":false,"company":"EMD SERONO","regulator":"FDA"}],"brandName":"Ovidrel","ecosystem":[{"indication":"Ulcerative colitis","otherDrugs":[{"name":"adalimumab","slug":"adalimumab","company":"Abbvie Inc"},{"name":"azathioprine","slug":"azathioprine","company":"Prometheus Labs"},{"name":"balsalazide","slug":"balsalazide","company":"Salix Pharms"},{"name":"cortisone acetate","slug":"cortisone-acetate","company":""}],"globalPrevalence":5000000}],"mechanism":{"target":"Lutropin-choriogonadotropic hormone receptor","novelty":"Follow-on","targets":[{"gene":"LHCGR","source":"DrugCentral","target":"Lutropin-choriogonadotropic hormone receptor","protein":"Lutropin-choriogonadotropic hormone receptor"}],"modality":"Small Molecule","drugClass":"Gonadotropin","explanation":"","oneSentence":"","technicalDetail":"Ovidrel is a recombinant human follicle-stimulating hormone (hFSH) analog that binds to the lutropin-choriogonadotropic hormone receptor, mimicking the action of natural FSH and LH hormones to stimulate follicular growth and ovulation."},"commercial":{"launchDate":"2000","_launchSource":"DrugCentral (FDA 2000-09-20, EMD SERONO)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5149","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=CHORIOGONADOTROPIN%20ALFA","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CHORIOGONADOTROPIN ALFA","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T09:36:24.142748","_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T00:22:35.907710+00:00","fieldsConflicting":15,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"chorionic gonadotrophin","drugSlug":"chorionic-gonadotrophin","fdaApproval":"","relationship":"same-class"},{"drugName":"follitropin","drugSlug":"follitropin","fdaApproval":"1986-09-18","relationship":"same-class"},{"drugName":"lutropin alfa","drugSlug":"lutropin-alfa","fdaApproval":"2004-10-08","relationship":"same-class"}],"genericName":"choriogonadotropin alfa","indications":{"approved":[{"name":"Ulcerative colitis","source":"DrugCentral","snomedId":64766004,"regulator":"FDA","usPrevalence":900000,"globalPrevalence":5000000,"prevalenceMethod":"curated","prevalenceSource":"Lancet Gastroenterology, 2023"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"chorionic-gonadotrophin","brandName":"chorionic gonadotrophin","genericName":"chorionic gonadotrophin","approvalYear":"","relationship":"same-class"},{"drugId":"follitropin","brandName":"follitropin","genericName":"follitropin","approvalYear":"1986","relationship":"same-class"},{"drugId":"lutropin-alfa","brandName":"lutropin alfa","genericName":"lutropin alfa","approvalYear":"2004","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT07425990","phase":"NA","title":"FET-LET-2x2: Clinical Pregnancy Rates After Frozen Embryo Transfer in Natural and Modified Natural Cycles","status":"NOT_YET_RECRUITING","sponsor":"University of Novi Sad","startDate":"2026-02","conditions":["Infertility Female","Frozen Embryo Transfer (FET)"],"enrollment":120,"completionDate":"2027-03"},{"nctId":"NCT06440850","phase":"PHASE2","title":"Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2024-07-15","conditions":["Thyroid Gland Follicular Carcinoma","Thyroid Gland Oncocytic Carcinoma","Thyroid Gland Papillary Carcinoma"],"enrollment":21,"completionDate":"2026-11-22"},{"nctId":"NCT03428165","phase":"NA","title":"Transfer of Frozen Embryos in Natural Cycle: Evaluation of Impact of Spontaneous Versus HCG-triggered Ovulation on Pregnancy Rate","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2018-03-07","conditions":["in Vitro Fertilization"],"enrollment":103,"completionDate":"2022-02-01"},{"nctId":"NCT06879002","phase":"","title":"Comparing IVF/ICSI Cycle Outcomes of Post Ovulation Ovarian Stimulation Protocol With Elonva Without GnRH Antagonist to Follicular Phase Day 2 Stimulation Fixed Day 5 Antagonist Protocol","status":"NOT_YET_RECRUITING","sponsor":"ART Fertility Clinics LLC","startDate":"2025-12-30","conditions":["Stimulation in the Ovary","IVF Outcome"],"enrollment":252,"completionDate":"2026-12-30"},{"nctId":"NCT07128394","phase":"NA","title":"Extra Luteinizing Hormone Improve Embryo Quality in IVF Patients With Low LH During Long GnRH-Agonist Treatment","status":"RECRUITING","sponsor":"Nanjing University","startDate":"2024-02-01","conditions":["Infertility, Female","Luteinizing Hormone (LH)"],"enrollment":590,"completionDate":"2026-11-30"},{"nctId":"NCT06896617","phase":"PHASE4","title":"Impact of the Presence of the Corpus Luteum on Pregnancies Obtained Through Frozen Embryo Transfer(FET)","status":"RECRUITING","sponsor":"Fundacion Clinic per a la Recerca Biomédica","startDate":"2025-02-01","conditions":["Infertilities","Embryo Transfer"],"enrollment":334,"completionDate":"2026-12-20"},{"nctId":"NCT03737253","phase":"NA","title":"Hormone Evaluation in Artificial Reproductive Technology","status":"COMPLETED","sponsor":"Lund University","startDate":"2016-09","conditions":["Female Infertility"],"enrollment":810,"completionDate":"2024-10-02"},{"nctId":"NCT06572930","phase":"","title":"Serum FSH Monitoring for Identification of an Optimal Range During Ovarian Stimulation","status":"RECRUITING","sponsor":"ART Fertility Clinics LLC","startDate":"2024-12-16","conditions":["Ovarian Stimulation"],"enrollment":150,"completionDate":"2025-12-01"},{"nctId":"NCT04997525","phase":"PHASE4","title":"Estradiol and Progesterone Levels Following Frozen Embryo Transfer","status":"COMPLETED","sponsor":"Copenhagen University Hospital at Herlev","startDate":"2021-04-20","conditions":["Infertility"],"enrollment":305,"completionDate":"2024-12-06"},{"nctId":"NCT00702338","phase":"","title":"Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial P05693 (P05713)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2008-05-15","conditions":["Pregnancy","Neonates"],"enrollment":1,"completionDate":"2008-12-15"},{"nctId":"NCT00702520","phase":"","title":"Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial 38833 (P05783)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-04-01","conditions":["Pregnancy","Neonates"],"enrollment":15,"completionDate":"2008-01-15"},{"nctId":"NCT00702806","phase":"PHASE2","title":"Investigate Dose of Org 36286 to Initiate Multiple Follicular Growth in a Controlled Ovarian Hyperstimulation Protocol for IVF or IVF/ICSI (P07015)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2001-07-01","conditions":["Infertility","In Vitro Fertilization"],"enrollment":99,"completionDate":"2002-10-15"},{"nctId":"NCT06396390","phase":"PHASE4","title":"Comparison of Progestin Primed Ovarian Stimulation (PPOS) vs.GnRH Antagonist Methods on IVF Outcomes","status":"NOT_YET_RECRUITING","sponsor":"Nesta Clinic","startDate":"2024-08-01","conditions":["IVF","Fertility Issues","Infertility"],"enrollment":152,"completionDate":"2026-08-01"},{"nctId":"NCT00696800","phase":"PHASE3","title":"A Study to Investigate the Efficacy and Safety of a Single Injection of Corifollitropin Alfa (Organon 36286) for Ovarian Stimulation Using Daily Recombinant Follicle Stimulating Hormone (FSH) as Reference (P05787)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-06-27","conditions":["In Vitro Fertilization"],"enrollment":1509,"completionDate":"2008-01-15"},{"nctId":"NCT00702845","phase":"PHASE3","title":"To Investigate Efficacy and Safety of a Single Injection of Org 36286 for Ovarian Stimulation Using Daily Recombinant FSH as Reference (Ensure)(P05690/MK-8962-001)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-12-28","conditions":["Infertility"],"enrollment":397,"completionDate":"2007-11-15"},{"nctId":"NCT00697255","phase":"PHASE2","title":"A Phase 2 Trial to Evaluate if Corifollitropin Alfa (Org 36286), Followed by a Low Daily Dose of hCG or Recombinant FSH Can Induce Monofollicular Growth in Women With WHO Group II Anovulatory Infertility (P05693)","status":"TERMINATED","sponsor":"Organon and Co","startDate":"2007-05-15","conditions":["Ovulation Induction"],"enrollment":8,"completionDate":"2008-05-15"},{"nctId":"NCT01709331","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Corifollitropin Alfa (MK-8962) in Combination With Human Chorionic Gonadotropin (hCG) in Adult Men With Hypogonadotropic Hypogonadism (HH) (P07937)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2013-02-11","conditions":["Hypogonadism","Hypogonadotropic Hypogonadism"],"enrollment":18,"completionDate":"2015-04-08"},{"nctId":"NCT03019575","phase":"PHASE3","title":"Efficacy and Safety of Corifollitropin Alfa (MK-8962) in Combination With Human Chorionic Gonadotropin (hCG) in Adolescent Males With Hypogonadotropic Hypogonadism (HH) (MK-8962-043)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2017-02-02","conditions":["Hypogonadotropic Hypogonadism"],"enrollment":17,"completionDate":"2020-05-05"},{"nctId":"NCT03846544","phase":"PHASE4","title":"Double Pick up in Poor Prognosis Women","status":"COMPLETED","sponsor":"CRG UZ Brussel","startDate":"2019-10-01","conditions":["Fertility Disorders"],"enrollment":48,"completionDate":"2022-10-01"},{"nctId":"NCT03564509","phase":"PHASE2","title":"A Trial to Investigate the Efficacy and Safety of FE 999302 as add-on Treatment to Follitropin Delta (REKOVELLE) in Women Undergoing Controlled Ovarian Stimulation.","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2018-05-14","conditions":["Controlled Ovarian Stimulation"],"enrollment":620,"completionDate":"2020-01-08"},{"nctId":"NCT04189133","phase":"PHASE2","title":"Rec-LH PD and Safety Profile in Hypogonadotropic Hypogonadism Men","status":"UNKNOWN","sponsor":"Azienda Ospedaliero-Universitaria di Modena","startDate":"2022-01-19","conditions":["Acquired Hypogonadotropic Hypogonadism"],"enrollment":32,"completionDate":"2026-01-18"},{"nctId":"NCT05638529","phase":"PHASE4","title":"Dual Trigger\" in IVF Patients at High Risk of Ovarian Hyper Stimulation Syndrome","status":"UNKNOWN","sponsor":"Mount Sinai Hospital, Canada","startDate":"2019-05-01","conditions":["Ovarian Hyperstimulation Syndrome","Infertility, Female"],"enrollment":80,"completionDate":"2023-12-31"},{"nctId":"NCT04446845","phase":"PHASE4","title":"Double Stimulation Followed by a Fresh Embryo Transfer","status":"COMPLETED","sponsor":"Fundación Santiago Dexeus Font","startDate":"2020-10-30","conditions":["Infertility"],"enrollment":120,"completionDate":"2023-05-02"},{"nctId":"NCT05778331","phase":"","title":"The Difference Between POSEIDON Group 3 and Group 4 as Regards IVF","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2023-01-10","conditions":["Infertility, Female","IVF"],"enrollment":340,"completionDate":"2023-09"},{"nctId":"NCT05450900","phase":"EARLY_PHASE1","title":"Can Biotin Supplementation be Used to Mask hCG Abuse?","status":"COMPLETED","sponsor":"Sports Medicine Research and Testing Laboratory","startDate":"2022-10-27","conditions":["Healthy"],"enrollment":10,"completionDate":"2023-02-02"},{"nctId":"NCT02402192","phase":"PHASE4","title":"Type of Gonadotropin and Embryo Kinetics of Development","status":"TERMINATED","sponsor":"IVI Madrid","startDate":"2015-04","conditions":["Infertility"],"enrollment":201,"completionDate":"2016-12"},{"nctId":"NCT03660813","phase":"NA","title":"Follicle Size and Oocyte Development","status":"COMPLETED","sponsor":"Sheba Medical Center","startDate":"2018-07-01","conditions":["IVF Treatment"],"enrollment":200,"completionDate":"2021-08-01"},{"nctId":"NCT05321511","phase":"PHASE4","title":"Comparison of Triggers in Double Ovarian Stimulation (DuoStim).","status":"UNKNOWN","sponsor":"Instituto Bernabeu","startDate":"2022-03-03","conditions":["IVF","LOW OVARIAN RESPONSE"],"enrollment":165,"completionDate":"2023-03-31"},{"nctId":"NCT01599494","phase":"PHASE3","title":"An Efficacy and Safety Study of Corifollitropin Alfa (MK-8962) in Contrast to Recombinant FSH for Use in Controlled Ovarian Stimulation of Indian Women (P07056, Also Known as MK-8962-029)","status":"WITHDRAWN","sponsor":"Organon and Co","startDate":"2014-03","conditions":["Infertility"],"enrollment":0,"completionDate":"2015-06"},{"nctId":"NCT01297465","phase":"PHASE3","title":"PERgoveriS In Stratified Treatment for Assisted Reproductive Technique","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2011-05-31","conditions":["Assisted Reproductive Techniques","Reproductive Technology, Assisted"],"enrollment":202,"completionDate":"2012-10-31"},{"nctId":"NCT03876145","phase":"NA","title":"The Four Methods of Ovarian Stimulation in Patients With Polycystic Ovarian Syndrome","status":"COMPLETED","sponsor":"Royan Institute","startDate":"2016-11-12","conditions":["Polycystic Ovary Syndrome","Ovarian Hyperstimulation Syndrome"],"enrollment":120,"completionDate":"2020-11-20"},{"nctId":"NCT01319695","phase":"PHASE1,PHASE2","title":"Corifollitropin Alfa Versus Recombinant Follicle Stimulating Hormone (FSH) in Ovarian Stimulation of Women Undergoing in Vitro Fertilisation","status":"COMPLETED","sponsor":"National and Kapodistrian University of Athens","startDate":"2011-01","conditions":["Infertility"],"enrollment":140,"completionDate":"2017-08"},{"nctId":"NCT03208972","phase":"PHASE4","title":"Elonva in Combination With Hp-FSH Versus Elonva With Low Dose hCG","status":"COMPLETED","sponsor":"AZ Jan Palfijn Gent","startDate":"2014-10","conditions":["Infertility"],"enrollment":107,"completionDate":"2015-11"},{"nctId":"NCT03857230","phase":"PHASE1","title":"The Safety and Pharmacokinetics of Primapur and Gonal-f","status":"COMPLETED","sponsor":"IVFarma LLC","startDate":"2015-10-29","conditions":["Area Under Curve","Pharmacokinetics","Absorption"],"enrollment":28,"completionDate":"2016-05-10"},{"nctId":"NCT02145247","phase":"NA","title":"Ovarian Morphology and Theca Cell Androgen Production in Women With Polycystic Ovary Syndrome (PCOS)","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2014-05","conditions":["Polycystic Ovary Syndrome"],"enrollment":39,"completionDate":"2018-01"},{"nctId":"NCT03954197","phase":"NA","title":"Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients","status":"UNKNOWN","sponsor":"Hôpital Jean Verdier","startDate":"2014-09-09","conditions":["Fertility Preservation","Breast Cancer"],"enrollment":204,"completionDate":"2019-10-09"},{"nctId":"NCT02834117","phase":"PHASE4","title":"Natural Cycle Versus Stimulated Cycle Before Frozen Embryo Transfer","status":"COMPLETED","sponsor":"Dr Massin Nathalie","startDate":"2015-05","conditions":["Fertility"],"enrollment":124,"completionDate":"2018-03"},{"nctId":"NCT02606500","phase":"PHASE4","title":"Efficacy of Corifollitropin Alfa in Obese Women in Terms of Clinical and Molecular Parameters of IVF Success","status":"COMPLETED","sponsor":"University Medical Centre Ljubljana","startDate":"2016-03","conditions":["Obesity"],"enrollment":70,"completionDate":"2017-03"},{"nctId":"NCT01112358","phase":"PHASE2","title":"Lutropin Alfa in Women at Risk of Poor Response","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2005-12-07","conditions":["Ovarian Stimulation"],"enrollment":58,"completionDate":"2007-01-30"},{"nctId":"NCT02607293","phase":"","title":"A Study to Explore Correlation Between Symptoms and Signs of Polycystic Ovarian Syndrome (PCOS) and Risk of Over-response to Ovarian Stimulation","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2015-12-31","conditions":["Polycystic Ovary Syndrome"],"enrollment":1064,"completionDate":"2017-06-28"},{"nctId":"NCT00989781","phase":"NA","title":"Mechanisms of Increased Androgen Production Among Women With Polycystic Ovary Syndrome","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2009-09","conditions":["Polycystic Ovary Syndrome"],"enrollment":41,"completionDate":"2013-09"},{"nctId":"NCT01183143","phase":"PHASE3","title":"Convenience and Safety of Assisted Reproductive Technology Procedures Using a Gonal-F Filled by Mass (Fbm) Liquid Formulation Applied by Pen for Ovulation Induction and In-vitro Fertilization","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2004-05-11","conditions":["Infertility","Ovulation Induction","In-Vitro Fertilization"],"enrollment":215,"completionDate":"2006-03-02"},{"nctId":"NCT03480412","phase":"","title":"Second Step Protocol in Poor Ovarian Responder (POR)","status":"UNKNOWN","sponsor":"Università degli Studi 'G. d'Annunzio' Chieti e Pescara","startDate":"2017-09-01","conditions":["Infertility, Female","Premature Ovarian Failure","Fertility Disorders"],"enrollment":50,"completionDate":"2019-09"},{"nctId":"NCT00249834","phase":"PHASE4","title":"Safety and Efficacy of Pre-defined, Fixed Dose of Gonal-f Pen Based on Subject Baseline Characteristics in Subjects Undergoing in Vitro Fertilization (IVF)","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2004-09-22","conditions":["Infertility"],"enrollment":166,"completionDate":"2006-01-16"},{"nctId":"NCT01110707","phase":"PHASE2","title":"A Randomised, Phase II, Comparative Study With a Parallel Control for Evaluating the Efficacy and Safety of Combined Treatment of Lutropin Alpha and Recombinant Human Luteinizing Hormone in the Middle of the Controlled Ovarian Stimulation Follicular Phase in Women With Reduced Ovarian Reserve","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2005-01-10","conditions":["Infertility","Ovulation Induction"],"enrollment":131,"completionDate":"2006-11-15"},{"nctId":"NCT01687712","phase":"PHASE3","title":"Phase III Study Comparing Efficacy and Safety of AFOLIA vs Gonal-f® RFF in Women (35 to 42) Undergoing IVF","status":"COMPLETED","sponsor":"Fertility Biotech AG","startDate":"2013-11-25","conditions":["Infertility"],"enrollment":1100,"completionDate":"2016-11-14"},{"nctId":"NCT03118830","phase":"PHASE4","title":"Long Protocol and Freeze All Embryos vs Antagonist Protocol With Fresh Embryo Transfer in PCOS Patients Undergoing ICSI","status":"COMPLETED","sponsor":"Cairo University","startDate":"2017-04-21","conditions":["Invitro Fertilization"],"enrollment":204,"completionDate":"2017-11-03"},{"nctId":"NCT02047227","phase":"PHASE3","title":"Phase 3 Study to Evaluate the Efficacy and Safety of Pergoveris® in Assisted Reproductive Technology (ESPART)","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2014-01-31","conditions":["Infertility"],"enrollment":939,"completionDate":"2015-08-31"},{"nctId":"NCT02118051","phase":"PHASE3","title":"Effect of Treatment With Corifollitropin Alpha in Vitro Fertilization in Patients With Poor Ovarian Response.","status":"COMPLETED","sponsor":"Instituto de Investigacion Sanitaria La Fe","startDate":"2013-09","conditions":["Infertility"],"enrollment":234,"completionDate":"2017-06"},{"nctId":"NCT03071172","phase":"PHASE3","title":"Clinical Study of Recombinant Human Follitropin for Injection Assisted in COH Assisted IVF-ET","status":"UNKNOWN","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","startDate":"2017-03","conditions":["Ovarian Hyperstimulation Syndrome"],"enrollment":252,"completionDate":"2018-05"},{"nctId":"NCT02825290","phase":"PHASE4","title":"Modified Luteal Support for Frozen-Thawed Embryo Transfer - A Prospective Study","status":"UNKNOWN","sponsor":"Sheba Medical Center","startDate":"2016-07","conditions":["Embryo Transfer","Luteal Support"],"enrollment":62,"completionDate":"2017-06"},{"nctId":"NCT01871532","phase":"PHASE4","title":"Low-dose Gonal-f® in Ovulation Induction","status":"TERMINATED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2013-07","conditions":["Infertility","Monofollicular Development"],"enrollment":24,"completionDate":"2014-11"},{"nctId":"NCT02349945","phase":"PHASE2,PHASE3","title":"FSH Receptor Polymorphism p.N680S and Efficacy of FSH Therapy","status":"COMPLETED","sponsor":"Azienda USL Modena","startDate":"2011-01","conditions":["Male Infertility"],"enrollment":88,"completionDate":"2015-12"},{"nctId":"NCT01653743","phase":"PHASE3","title":"Trial to Assess the Clinical Efficacy and Safety of MSJ-0011 in Inducing Ovulation in Anovulatory or Oligo-ovulatory Japanese Women","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2012-09","conditions":["Anovulation","Oligo-ovulation","Hypothalamic-pituitary Dysfunction","Polycystic Ovarian Syndrome"],"enrollment":81,"completionDate":"2014-12"},{"nctId":"NCT01497197","phase":"PHASE3","title":"A Trial to Compare the Efficacy and Safety of Ovarian Stimulation With GONAL-f® and Luveris® Starting on Day 1 Versus Day 6 in Women Undergoing Assisted Reproductive Technique","status":"TERMINATED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2012-05","conditions":["Infertility","Fertility","Follicle Stimulating Hormone Deficiency"],"enrollment":174,"completionDate":"2014-01"},{"nctId":"NCT02442895","phase":"","title":"Biomarkers of Ovarian Reserve and Correlation With IVF Treatments","status":"COMPLETED","sponsor":"U.O.S. Procreazione Medicalmente Assistita e Congelamento Gameti","startDate":"2014-02","conditions":["Pregnancy, Ovarian"],"enrollment":236,"completionDate":"2015-02"},{"nctId":"NCT02437032","phase":"PHASE4","title":"Gonadotropin Type in Ovarian Stimulation","status":"COMPLETED","sponsor":"IVI Madrid","startDate":"2009-04","conditions":["Infertility"],"enrollment":100,"completionDate":"2012-12"},{"nctId":"NCT02140515","phase":"PHASE4","title":"Comparison of Assisted Reproductive Technology (ART) Outcomes Between Two Protocols of Induction of Ovulation in Patients With Hypogonadotropic Hypogonadism","status":"UNKNOWN","sponsor":"Royan Institute","startDate":"2012-11","conditions":["Infertility"],"enrollment":90,"completionDate":"2016-11"},{"nctId":"NCT02244866","phase":"NA","title":"Efficacy of Pergoveris in Aged IVF Patients","status":"COMPLETED","sponsor":"Vietnam National University","startDate":"2012-10","conditions":["Infertility"],"enrollment":240,"completionDate":"2014-06"},{"nctId":"NCT01100333","phase":"","title":"GONAL-f CONSORT (Consistency in r-hFSH Starting Doses for Individualised Treatment)","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2008-04","conditions":["Infertility"],"enrollment":2552,"completionDate":"2011-07"},{"nctId":"NCT01115725","phase":"","title":"A Study to Evaluate the Ease of Use, Local Tolerance, Safety and Effectiveness of Gonal-f® (Filled-by-mass in a Prefilled Pen)","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2005-11","conditions":["Infertility"],"enrollment":76,"completionDate":"2008-07"},{"nctId":"NCT01111084","phase":"","title":"A Prospective, Multi-centric Observational Study to Determine the Mono-bifollicular Development in Infertile Women Subjected to Ovulation Induction With Follitropin α","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2004-03","conditions":["Ovulation Induction"],"enrollment":410,"completionDate":"2005-06"},{"nctId":"NCT01080729","phase":"","title":"An Observational Study to Compare the Dose of Gonal-fTM FbM Prescribed by the Doctor With the Recommendation of the Dose Calculator Consort and to Evaluate the Ease of Use of Pre-filled Pen of Gonal-fTM FbM Pen","status":"TERMINATED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2009-02","conditions":["Multifollicular Stimulation"],"enrollment":25,"completionDate":"2010-02"},{"nctId":"NCT00298025","phase":"PHASE4","title":"A Study to Compare the Safety and Efficacy of Cetrotide® 3 Milligram (mg) Versus Antagon™ in Women Undergoing Ovarian Stimulation","status":"COMPLETED","sponsor":"EMD Serono","startDate":"2003-09","conditions":["Infertile Women Undergoing Assisted Reproductive Technology (ART)"],"enrollment":185,"completionDate":"2004-05"},{"nctId":"NCT01100346","phase":"","title":"Predictive Factors of Ovarian Response in Ovulation Induction With Intrauterine Insemination of a Gonal-f Low-dose Regimen","status":"TERMINATED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2010-01","conditions":["Infertility"],"enrollment":30,"completionDate":"2010-09"},{"nctId":"NCT01225835","phase":"PHASE4","title":"Progesterone Serum Levels in Subfertile Female Patients Undergoing in Vitro Fertilisation (IVF)","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2010-10","conditions":["Infertility"],"enrollment":124,"completionDate":"2013-06"},{"nctId":"NCT01079949","phase":"PHASE2","title":"A Phase II Study to Assess the Efficacy and Safety of Luveris® (Lutropin Alfa) in Mid Follicular Phase for Controlled Ovarian Stimulation (COS) in Advanced Reproductive Age","status":"TERMINATED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2007-11","conditions":["Infertility","Ovulation Induction"],"enrollment":93,"completionDate":"2010-10"},{"nctId":"NCT01075815","phase":"PHASE2","title":"A Clinical Trial to Determine the Effect of Lutropin Alfa on Embryo Quality and Implantation Rate in Advanced Reproductive Age","status":"TERMINATED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2008-11","conditions":["Infertility","Ovulation Induction"],"enrollment":76,"completionDate":"2010-10"},{"nctId":"NCT00505752","phase":"PHASE2","title":"Investigation of a Long-Acting Follicle Stimulating Hormone in Infertile Women Undergoing Assisted Reproductive Technology (ART)","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2007-01","conditions":["Infertility"],"enrollment":520,"completionDate":"2008-09"},{"nctId":"NCT00553514","phase":"PHASE2","title":"AS900672-Enriched in Ovulation Induction","status":"TERMINATED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2007-12","conditions":["Ovulation Induction"],"enrollment":71,"completionDate":"2009-03"},{"nctId":"NCT01081626","phase":"PHASE4","title":"Recombinant Follicle Stimulating Hormone (FSH) (Gonal-f®): Use in Ovulation Induction","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2009-03","conditions":["Ovulation Induction"],"enrollment":310,"completionDate":"2011-03"},{"nctId":"NCT00829244","phase":"PHASE4","title":"CONSORT Randomized Controlled Trial in Assisted Reproductive Technology","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2008-08","conditions":["Infertility"],"enrollment":200,"completionDate":"2010-01"},{"nctId":"NCT01185704","phase":"PHASE3","title":"Analysis of Two Therapeutic With Cetrotide® in Polycystic Ovarian (PCO) Women in Assisted Reproductive Technology (ART)","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2008-11","conditions":["Polycystic Ovarian Syndrome"],"enrollment":136,"completionDate":"2012-02"},{"nctId":"NCT01735422","phase":"PHASE2","title":"A Study to Evaluate Safety and Efficacy of Recombinant Human Luteinizing Hormone (r-hLH) Compared With Urinary Human Chorionic Gonadotrophin (u-hCG) to Trigger Ovulation in Infertile Women","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"1999-12","conditions":["Infertility"],"enrollment":67,"completionDate":"2001-07"},{"nctId":"NCT01210144","phase":"PHASE4","title":"EXpression PRofile Endometrium Samples Study","status":"TERMINATED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2008-08","conditions":["In Vitro Fertilization"],"enrollment":27,"completionDate":"2010-08"},{"nctId":"NCT01084265","phase":"PHASE3","title":"A Study Using Recombinant Human Luteinizing Hormone (r-hLH, Luveris®) in the Treatment of Chinese Women With Hypogonadotropic Hypogonadism","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2004-02","conditions":["Hypogonadism"],"enrollment":31,"completionDate":"2005-12"},{"nctId":"NCT00230815","phase":"PHASE3","title":"A Phase 3b Study to Evaluate Subject Satisfaction With Follitropin Alfa Injection in Oligoanovulatory Infertile Women Undergoing Ovulation Induction","status":"COMPLETED","sponsor":"EMD Serono","startDate":"2004-07","conditions":["Infertility"],"enrollment":62,"completionDate":"2005-11"},{"nctId":"NCT01668056","phase":"NA","title":"Synchronization of Ovarian Stimulation for in Vitro Fertilization With Follicular Wave Emergence","status":"UNKNOWN","sponsor":"University of Sao Paulo General Hospital","startDate":"2012-01","conditions":["Infertility"],"enrollment":30,"completionDate":"2014-12"},{"nctId":"NCT00328926","phase":"PHASE4","title":"Luveris® (Lutropin Alfa for Injection) in Women With Hypogonadotropic Hypogonadism (Luteinizing Hormone [LH] Less Than [<] 1.2 International Unit Per Liter [IU/L])","status":"TERMINATED","sponsor":"EMD Serono","startDate":"2006-03","conditions":["Hypogonadotropic Hypogonadism"],"enrollment":11,"completionDate":"2012-05"},{"nctId":"NCT01152866","phase":"","title":"An Open Label, Canadian Phase IIIb Study With Ovidrel in Ovulation Induction (OI) and Assisted Reproductive Technique (ART)","status":"COMPLETED","sponsor":"EMD Serono","startDate":"2003-12","conditions":["Ovulation Induction","Infertility"],"enrollment":3,"completionDate":"2004-12"},{"nctId":"NCT01760278","phase":"PHASE4","title":"Assessment of Implantation Potential of Embryos by Time-lapse Technology","status":"UNKNOWN","sponsor":"Bloom IVF and Fertility Centre","startDate":"2012-12","conditions":["Embryo/Fetus Death","Blastocyst Disintegration","Aneuploidy","Complication of Implant","Chemical Pregnancy"],"enrollment":200,"completionDate":"2013-04"},{"nctId":"NCT00883766","phase":"NA","title":"Polycystic Ovary Syndrome (PCOS) and In Vitro Fertilization (IVF): A Comparison Between Standard Long Protocol Versus an Antagonist Protocol Starting on Day 1","status":"TERMINATED","sponsor":"Fundacion Dexeus","startDate":"2009-04","conditions":["Polycystic Ovary Syndrome","In Vitro Fertilization"],"enrollment":172,"completionDate":"2012-06"},{"nctId":"NCT00938314","phase":"PHASE2","title":"Study of NTx®-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients","status":"TERMINATED","sponsor":"Stem Cell Therapeutics Corp.","startDate":"2009-08","conditions":["Stroke"],"enrollment":96,"completionDate":"2010-04"},{"nctId":"NCT00715364","phase":"PHASE2","title":"REGENESIS (US): A Phase IIb Prospective, Randomized, Double-blind, Placebo Controlled Study of NTx™-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients","status":"WITHDRAWN","sponsor":"Stem Cell Therapeutics Corp.","startDate":"2009-08","conditions":["Stroke"],"enrollment":30,"completionDate":"2010-09"},{"nctId":"NCT01239706","phase":"PHASE2","title":"Safety Study of Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Traumatic Brain Injury: Dosing Tier 1","status":"UNKNOWN","sponsor":"University of Calgary","startDate":"2010-11","conditions":["Traumatic Brain Injury"],"enrollment":10,"completionDate":"2012-06"},{"nctId":"NCT00439829","phase":"PHASE4","title":"Synchronization of Follicle Wave Emergence and Ovarian Stimulation","status":"COMPLETED","sponsor":"University of Saskatchewan","startDate":"2007-02","conditions":["Infertility"],"enrollment":80,"completionDate":"2010-05"},{"nctId":"NCT00823121","phase":"PHASE1,PHASE2","title":"Replacement of Fresh Embryo Transfers (ETs) by Frozen Embryo Transfers (FETs) Using Vitrification","status":"UNKNOWN","sponsor":"Yazd Research & Clinical Center for Infertility","startDate":"2008-08","conditions":["In Vitro Fertilization"],"enrollment":500,"completionDate":"2009-12"},{"nctId":"NCT01029470","phase":"PHASE2","title":"To Describe the Effect of rhLH Supplementation in Women With Hyporesponse to rhFSH After Pituitary Downregulation","status":"UNKNOWN","sponsor":"Peking University Third Hospital","startDate":"2009-12","conditions":["Infertility"],"enrollment":150,"completionDate":"2011-03"},{"nctId":"NCT00663416","phase":"PHASE2","title":"REGENESIS (CA): A Study of NTx™-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients","status":"TERMINATED","sponsor":"Stem Cell Therapeutics Corp.","startDate":"2008-03","conditions":["Stroke"],"enrollment":134,"completionDate":"2009-01"},{"nctId":"NCT00948805","phase":"PHASE3","title":"Evaluation of the Luteolytic Effect of a Gonadotropin Releasing Hormone (GnRH) Agonist After the Administration of Human Chorionic Gonadotropin (hCG) in the Initial Follicular Phase a Its Influence on the Prognosis of in Vitro Fertilization Treatment","status":"UNKNOWN","sponsor":"University of Sao Paulo","startDate":"2009-01","conditions":["Infertility"],"enrollment":25,"completionDate":"2010-07"},{"nctId":"NCT00553293","phase":"PHASE4","title":"Nordic Luveris Study","status":"COMPLETED","sponsor":"Rigshospitalet, Denmark","startDate":"2003-08","conditions":["Infertility","In Vitro Fertilization"],"enrollment":526,"completionDate":"2004-11"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Subcutaneous","formulation":"Injection","formulations":[{"form":"INJECTION, SOLUTION","route":"SUBCUTANEOUS","productName":"Ovidrel"}]},"crossReferences":{"MMSL":"15777","NDDF":"009029","UNII":"6413W06WR3","VANDF":"4021245","INN_ID":"7473","RXNORM":"283550","UMLSCUI":"C0937609","chemblId":"CHEMBL1201464","ChEMBL_ID":"CHEMBL1201464","KEGG_DRUG":"D03478","DRUGBANK_ID":"DB00097","SNOMEDCT_US":"129494006","MESH_SUPPLEMENTAL_RECORD_UI":"C412828"},"formularyStatus":[],"originalProduct":{"form":"INJECTION, SOLUTION","route":"SUBCUTANEOUS","company":"EMD Serono, Inc.","brandName":"Ovidrel","isOriginal":true,"marketingStatus":"BLA"},"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"2000-","companyName":"Emd Serono","relationship":"Original Developer"}],"publicationCount":16,"therapeuticAreas":["Immunology"],"atcClassification":{"source":"DrugCentral","atcCode":"G03GA08","allCodes":["G03GA08"]},"biosimilarFilings":[],"originalDeveloper":"Emd Serono","recentPublications":[{"date":"2025 Dec","pmid":"41473569","title":"Optimal timing for triggering oocyte maturation during in vitro fertilization cycles varies between gonadotropin-releasing hormone agonist and human chorionic gonadotropin use.","journal":"F&S reports"},{"date":"2025 Nov","pmid":"41426754","title":"IgA Vasculitis With Nephritis Following Controlled Ovarian Stimulation and Oocyte Donation.","journal":"Cureus"},{"date":"2025 Mar 7","pmid":"40142278","title":"Comparison of Effects of Chorionic Gonadotropin Alfa and Anastrozole on Sperm Retrieval Rate in Patients with Non-Mosaic Klinefelter Syndrome Following Microdissection Testicular Sperm Extraction.","journal":"Medicina (Kaunas, Lithuania)"},{"date":"2024 May 22","pmid":"38775072","title":"Circadian serum progesterone variations on the day of frozen embryo transfer in a modified natural cycle protocol.","journal":"Human reproduction (Oxford, England)"},{"date":"2024 Feb","pmid":"38299472","title":"Dose accuracy of the follitropin alfa pen injector 2.0, the follitropin alfa:lutropin alfa 2:1 combination pen injector 2.0 and the choriogonadotropin alfa pen injector 1.0 used for fertility treatment.","journal":"Expert opinion on drug delivery"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"approved","companyName":"Merck KGaA","companyId":"merck","modality":"Recombinant protein","firstApprovalDate":"2000","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1999-11-23T00:00:00.000Z","mah":"ORGANON USA LLC","brand_name_local":null,"application_number":"BLA017692"},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":"2000-09-20T00:00:00.000Z","mah":"EMD SERONO","brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":"2000-09-20T00:00:00.000Z","mah":"EMD SERONO","brand_name_local":null,"application_number":null},{"country_code":"SA","regulator":"SFDA","status":"likely_approved","approval_date":"2000-09-20T00:00:00.000Z","mah":"EMD SERONO","brand_name_local":null,"application_number":null},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2000-09-20T00:00:00.000Z","mah":"EMD SERONO","brand_name_local":null,"application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":"2000-09-20T00:00:00.000Z","mah":"EMD SERONO","brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":"2000-09-20T00:00:00.000Z","mah":"EMD SERONO","brand_name_local":null,"application_number":null},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2007-07-30T00:00:00.000Z","mah":"EMD SERONO","brand_name_local":null,"application_number":"BLA021149"},{"country_code":"BE","regulator":"FAMHP","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Ovitrelle","application_number":null},{"country_code":"BG","regulator":"BDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Ovitrelle","application_number":null},{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Ovitrelle","application_number":"EMEA/H/C/000320"},{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Ovitrelle","application_number":null},{"country_code":"HR","regulator":"HALMED","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Ovitrelle","application_number":null},{"country_code":"CY","regulator":"PHS","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Ovitrelle","application_number":null},{"country_code":"CZ","regulator":"SUKL","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Ovitrelle","application_number":null},{"country_code":"DK","regulator":"DKMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Ovitrelle","application_number":null},{"country_code":"EE","regulator":"SAM","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Ovitrelle","application_number":null},{"country_code":"FI","regulator":"Fimea","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Ovitrelle","application_number":null},{"country_code":"FR","regulator":"ANSM","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Ovitrelle","application_number":null},{"country_code":"DE","regulator":"BfArM","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Ovitrelle","application_number":null},{"country_code":"GR","regulator":"EOF","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Ovitrelle","application_number":null},{"country_code":"HU","regulator":"OGYEI","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Ovitrelle","application_number":null},{"country_code":"IE","regulator":"HPRA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Ovitrelle","application_number":null},{"country_code":"IT","regulator":"AIFA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Ovitrelle","application_number":null},{"country_code":"LV","regulator":"ZVA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Ovitrelle","application_number":null},{"country_code":"LT","regulator":"VVKT","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Ovitrelle","application_number":null},{"country_code":"LU","regulator":"MS","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Ovitrelle","application_number":null},{"country_code":"MT","regulator":"MMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Ovitrelle","application_number":null},{"country_code":"NL","regulator":"MEB","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Ovitrelle","application_number":null},{"country_code":"PL","regulator":"URPL","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Ovitrelle","application_number":null},{"country_code":"PT","regulator":"Infarmed","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Ovitrelle","application_number":null},{"country_code":"RO","regulator":"ANMDMR","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Ovitrelle","application_number":null},{"country_code":"SK","regulator":"SIDC","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Ovitrelle","application_number":null},{"country_code":"SI","regulator":"JAZMP","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Ovitrelle","application_number":null},{"country_code":"ES","regulator":"AEMPS","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Ovitrelle","application_number":null},{"country_code":"SE","regulator":"MPA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Ovitrelle","application_number":null},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"AU","regulator":"TGA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Ovitrelle","application_number":null},{"country_code":"CH","regulator":"Swissmedic","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Ovitrelle","application_number":null},{"country_code":"NO","regulator":"NoMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Ovitrelle","application_number":null},{"country_code":"IS","regulator":"IMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Ovitrelle","application_number":null},{"country_code":"NZ","regulator":"Medsafe","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Ovitrelle","application_number":null},{"country_code":"AT","regulator":"AGES","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Ovitrelle","application_number":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T00:22:35.907710+00:00","fieldsConflicting":15,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}